Daily Archives: September 19, 2021

The FDA has given mobocertinib expedited approval for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations

September 19th, 2021 Lung cancer

September 2021: The FDA granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertion mutations, as.... Read More

The FDA has approved zanubrutinib for the treatment of Waldenstrom’s macroglobulinemia

September 19th, 2021 Blood cancer, Hematological Disorders

September 2021: For adult patients with Waldenström's macroglobulinemia, the FDA has approved zanubrutinib (Brukinsa, BeiGene) (WM).In ASPEN (NCT03053440), zanubrutinib was compared to ibrutinib in patients with MYD88 L265P mutation (MYD88MUT) .... Read More

Ivosidenib has been approved by the FDA for advanced or metastatic cholangiocarcinoma

September 19th, 2021 Cholangiocarcinoma

Sept 19, 2021: The Food and Drug Administration approved Ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mu.... Read More